Non-hormonal alternatives for the management of menopausal hot flushes. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines

被引:1
|
作者
Raccah-Tebeka, B. [1 ]
Boutet, G. [2 ]
Plu-Bureau, G. [3 ,4 ]
机构
[1] Hop Robert Debre, Serv Gynecol Obstet, Paris, France
[2] Ctr Hosp Univ Bordeaux, Grp Hosp Pellegrin, Ctr Alienor Aquitaine, Serv Chirurg Gynecol & Med Reprod,AGREGA, Pl Amelie Raba Leon, F-33000 Bordeaux, France
[3] Hop Cochin Port Royal, Unite Gynecol Med, Inserm U1153 Equipe EPOPEE, Paris, France
[4] Univ Paris, Paris, France
来源
关键词
Vasomotor symptoms; Menopause; Non-hormonal treatment; Phytoestrogens; Climacteric syndrome; Hot flashes; Non-pharmacological treatment; BREAST-CANCER SURVIVORS; QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; EVENING PRIMROSE OIL; DOUBLE-BLIND; VASOMOTOR SYMPTOMS; POLLEN EXTRACT; PHASE-III; AROMATHERAPY MASSAGE; HORMONE-THERAPY;
D O I
10.1016/j.gofs.2021.03.020
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
One of the major symptoms of climacteric syndrome is hot flushes (HF). They are most often experienced as very disabling. Estrogen therapy is the most effective treatment. However, it may be contraindicated in some women. The aim of this article is to provide a review of the scientific literature on pharmacological and non pharmacological alternatives in this context. Only randomized trials and meta-analyses of randomized trials were considered. This review shows that some treatments usually used in non-gynecological or endocrinological disease have significant effect in reducing the frequency and/or severity of HF. Hence, some selective serotonin reuptake inhibitors (paroxetine, citalopram and escitalopram), serotonin and norepinephrine reuptake inhibitors (venlafaxine, desvenlafaxine) gabapentin, pregabalin and clonidine have a statistically effect as compared with placebo in reducing, the frequency and/or severity of HF. Some phytoestrogens, such as genistein, may also reduce the frequency of HF. Regarding non-pharmacological interventions, hypnosis, acupuncture or yoga have been analyzed with significant beneficial results, even if their evaluation is difficult by the absence of a good placebo group in most trials. By contrast, other approaches, both pharmacological or non-pharmacological, appear to be ineffective in the management of HT. These include homeopathy, vitamin E, alanine, omega 3, numerous phytoestrogens (red clover, black cohosh...), primrose oil, physical activity. In women suffering from breast cancer, several additional problems are added. On the one hand because all phytoestrogens are contraindicated and on the other hand, in patients using tamoxifen, because the molecules, that interact with CYP2D6, are to be formally avoided because of potential interaction with this anti-estrogen treatment. In conclusion, several pharmacological and non-pharmacological alternatives have significant efficacy in the management of severe HF. (C) 2021 Published by Elsevier Masson SAS.
引用
收藏
页码:373 / 393
页数:21
相关论文
共 50 条
  • [1] Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines (Short version)
    Tremollieres, F.
    Chabbert-Buffet, N.
    Plu-Bureau, G.
    Rousset-Jablonski, C.
    Lecerf, J-M
    Duclos, M.
    Pouilles, J-M
    Gosset, A.
    Boutet, G.
    Hocke, C.
    Maris, E.
    Hugon-Rodin, J.
    Maitrot-Mantelet, L.
    Robin, G.
    Andre, G.
    Hamdaoui, N.
    Mathelin, C.
    Lopes, P.
    Graesslin, O.
    Fritel, X.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 305 - 317
  • [2] Menopausal hormone therapy an cardiovascular risk. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Plu-Bureau, G.
    Mounier-Vehier, C.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 438 - 447
  • [3] How to diagnose menopause? Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Rousset-Jablonski, C.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 318 - 328
  • [4] Management of side effects under hormonal replacement therapy in menopausal women: Abnormal uterine bleeding. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines
    Hamdaoui, N.
    Boubli, L.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 474 - 484
  • [5] Nutritional advices for postmenopausal woman. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Lecerf, J-M
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 349 - 357
  • [6] Menopause hormone treatment. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Gosset, A.
    Robin, G.
    Letombe, B.
    Pouilles, J-M
    Tremollieres, F.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 358 - 372
  • [7] Effects of physical activity and decreased sedentary behaviours in menopausal women. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Duclos, M.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 335 - 348
  • [8] Menopause and risk of thromboembolic events. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Hugon-Rodin, J.
    Perol, S.
    Plu-Bureau, G.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 455 - 461
  • [9] Management of vulvovaginal atrophy: Physical therapies. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Maris, E.
    Salerno, J.
    Hedon, B.
    Mares, P.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 414 - 419
  • [10] Differential diagnosis of vasomotor symptoms. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Maitrot-Mantelet, L.
    Perol, S.
    Plu-Bureau, G.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 329 - 334